Cheniere Energy vs uniQure N.V. Ordinary Shares — how do they compare? Cheniere Energy trades at $280.51 (market cap $57.77B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.45B). The key difference: Cheniere Energy is far larger — about 39.8× uniQure N.V. Ordinary Shares's market cap, and Cheniere Energy pays a 0.79% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cheniere Energy for 12 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| LNG | QURE | |
|---|---|---|
Market Cap | $57.77B | $1.45B |
Volume | 1,602,545 | 3,323,243 |
Sector | Energy | Health |
52-Week High | $296.91 | $70.59 |
52-Week Low | $188.83 | $9.03 |
Typical Hold Time | 12 Days | 0 Days |
Enterprise Value | $83.22B | $707.46M |
Dividend Yield | 0.79% | — |
Signals from Pluang's Aura AI — not financial advice
Cheniere Energy (LNG) trades at $286.92, up 1.57% on the day, with a bullish technical signal from moving averages. The stock exhibits strong profitability with a 45.23% ROE and 13.57% net income margin, though Q1 2026 earnings missed expectations. Recent news highlights the company's long-term growth through a 22-year LNG supply deal with Petrobras, supporting its position in the energy sector.
The outlook is positive with a consensus price target of $307.44, representing 7.2% upside potential. Risks include earnings volatility and capital expenditure demands from growth projects. Analyst sentiment is overwhelmingly bullish with 92.59% buy ratings, but investors should monitor execution on expansion initiatives and energy market dynamics.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Cheniere Energy produces, liquefies, and exports natural gas as liquefied natural gas, or LNG. It operates large-scale LNG infrastructure along the U.S. Gulf Coast.
Read more on LNG →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →